European Patent Grants for IMP731 Antibody
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to European Patent Grants for IMP731 Antibody
August 25, 2016 9:13 AM EDT
Roth Capita affirms its Buy rating and $6 price target on Prima BioMed (Nasdaq: PBMD) after the company announced the granting of patent number 2142210 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease by the European Patent Office.
Analst Joseph Pantginis commented, We believe this patent award is an important milestone for Prima, which partnered the product with GSK, as the... More
August 25, 2016 7:47 AM EDT
Prima BioMed Ltd (NASDAQ: PBMD) announces the granting of patent number 2142210 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease by the European Patent Office.
The patent relates to Primas IMP731 antibody... More
